🇺🇸 FDA
Pipeline program

Anti-human CCL24 monoclonal antibody (CM-101)

CM-101-PSC-101

Phase 2 mab active

Quick answer

Anti-human CCL24 monoclonal antibody (CM-101) for Primary Sclerosing Cholangitis is a Phase 2 program (mab) at Chemomab Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Chemomab Therapeutics
Indication
Primary Sclerosing Cholangitis
Phase
Phase 2
Modality
mab
Status
active

Clinical trials